Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT

Bone Marrow Transplantation

Volumn 44, Issue 11, 2009, Pages 749-756

  Martino, R ^a   Piana J L ^a   Parody, R ^a   Valcarcel, D ^a   Sureda, A ^a   Brunet, S ^a   Briones, J ^a   Delgado, J ^a   Sanchez F ^a   Rabella, N ^a   Sierra, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Allogeneic hematopoietic SCT; Aspergillosis; Reduced intensity conditioning; Respiratory virus infections

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; ITRACONAZOLE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; RECIPIENT; REDUCED INTENSITY CONDITIONING; RESPIRATORY VIRUS; RISK FACTOR; VIRUS INFECTION;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRUS DISEASES; YOUNG ADULT;

EID: 75049083690     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.78     Document Type: Article

References (38)

1. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-540.
2. Martino R, Caballero MD, Canals C, San MJ, Sierra J, Rovira M et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 341-347. (Pubitemid 32834351)
3. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007; 139: 519-531.
4. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-833. (Pubitemid 36917771)
5. Martino R, Caballero MD, Canals C, Simon JA, Solano C, Urbano-Ispizua A et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001; 115: 653-659. (Pubitemid 34015658)
6. Perez-Simon JA, Martino R, Caballero D, Valcarcel D, Rebollo N, De la CR et al. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versushost disease prophylaxis. Biol Blood Marrow Transplant 2008; 14: 664-671.
7. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577-584.
8. Martino R, Perez-Simon JA, Moreno E, Queralto JM, Caballero D, Mateos M et al. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. Biol Blood Marrow Transplant 2005; 11: 437-447.
9. Perez-Simon JA, ez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005; 130: 394-403.
10. Subira M, Martino R, Sureda A, Altes A, Briones J, Brunet S et al. Safety and efficacy of low-dose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies. Methods Find Exp Clin Pharmacol 2001; 23: 505-510.
11. Rolston KV. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis 2004; 39(Suppl 1)1: S44-S48.
12. Hidalgo A, Parody R, Martino R, Sanchez F, Franquet T, Gimenez A et al. Correlation between high-resolution computed tomography and galactomannan antigenemia in adult hematologic patients at risk for invasive aspergillosis. Eur J Radiol (e-pub ahead of print 9 May 2008).
13. Martino R, Porras RP, Rabella N, Williams JV, Ramila E, Margall N et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11: 781-796.
14. Parody R, Rabella N, Martino R, Otegui M, del CM, Coll P et al. Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies. Am J Hematol 2007; 82: 807-811.
15. Williams JV, Martino R, Rabella N, Otegui M, Parody R, Heck JM et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis 2005; 192: 1061-1065.
16. Ascioglu S, Rex JH, De PB, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
17. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
18. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28: 1001-1011. (Pubitemid 34030645)
19. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001; 28: 909-915. (Pubitemid 33130231)
20. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
21. Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8: 512-520. (Pubitemid 35174825)
22. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-1050.
23. Jantunen E, Nihtinen A, Anttila VJ. Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients. Transpl Infect Dis 2008; 10: 156-161.
24. Mihu CN, King E, Yossepovitch O, Taur Y, Jakubowski A, Pamer E et al. Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation. Transpl Infect Dis 2008; 10: 162-167.
25. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002; 81: 233-243.
26. Martino R, Subira M, Rovira M, Solano C, Vazquez L, Sanz GF et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475-482.
27. Hasejima N, Yamato K, Takezawa S, Kobayashi H, Kadoyama C. Invasive pulmonary aspergillosis associated with influenza B. Respirology 2005; 10: 116-119.
28. Vandenbos F, Mondain-Miton V, Roger PM, Saint-Paul MC, Dellamonica P. Invasive pulmonary aspergillosis during influenza: a fortuitous association?]. Presse Med 1999; 28: 1755.
29. Alba D, Gomez-Cerezo J, Cobo J, Ripoll MM, Molina F, Vazquez JJ. Invasive pulmonary aspergillosis associated with influenza virus]. An Med Interna 1996; 13: 34-36.
30. Shapiro D, Ferriss J. Influenza A and aspergillosis. Chest 1986; 89: 318-319.
31. Lewis M, Kallenbach J, Ruff P, Zaltzman M, Abramowitz J, Zwi S. Invasive pulmonary aspergillosis complicating influenza A pneumonia in a previously healthy patient. Chest 1985; 87: 691-693.
32. Mezger M, Steffens M, Beyer M, Manger C, Eberle J, Toliat MR et al. Polymorphisms in the chemokine (C-X-C motif) ligand 10 are associated with invasive aspergillosis after allogeneic stem-cell transplantation and influence CXCL10 expression in monocyte-derived dendritic cells. Blood 2008; 111: 534-536.
33. Alonso JM. Immunity and pathophysiology of respiratory tract infections. Med Mal Infect 2008; 38: 433-437.
34. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol 2008; 143: 455-467.
35. Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359: 1766-1777.
36. Cordonnier C, Ribaud P, Herbrecht R, Milpied N, Valteau-Couanet D, Morgan C et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42: 955-963.
37. Subira M, Martino R, Franquet T, Puzo C, Altes A, Sureda A et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica 2002; 87: 528-534.
38. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-1184.